Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib prevents FBP from binding to v-ATPase-associated aldolase and activates lysosomal AMPK. Aldometanib can be used for the research of metabolic homeostasis [1].
| 説明 | Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib prevents FBP from binding to v-ATPase-associated aldolase and activates lysosomal AMPK. Aldometanib can be used for the research of metabolic homeostasis [1]. |
| In vitro | Aldometanib (0-1000 nM; 2 h) activates AMPK through preventing aldolase from binding to FBP to engender a pseudo-starvation signal [1]. Western Blot Analysis [1] Cell Line: Mouse primary hepatocytes, MEFs cells Concentration: 0-1000 nM Incubation Time: 2 h Result: Activated AMPK in mouse embryonic fibroblasts (MEFs) and mouse primary hepatocytes cells. Immunofluorescence [1] Cell Line: MEFs cells Concentration: 5 nM Incubation Time: 2 h Result: Inhibited TRPVs and induces AXIN lysosomal translocation. |
| In vivo | Aldometanib (oral; 0-10 mpk) lowers blood glucose in lean mice [1]. Aldometanib (oral; 2-10 mpk; twice daily; for a week) reduces blood glucose and alleviates fatty liver in obese hyperglycaemic mice [1]. Aldometanib alleviates fatty liver and nonalcoholic steatohepatitis [1]. Aldometanib (oral; 2mpk; twice-daily; for a month) alleviates liver fibrosis in NASH mice [1]. Aldometanib (oral; 0-50 μM; 0-50 days) extends lifespan in C. elegans via the lysosomal pathway [1]. Animal Model: Lean mice [1] Dosage: 0-10 mpk Administration: Oral Result: Decreased fasting blood glucose and improved glucose tolerance, promoted muscular TBC1D1 phosphorylation and glucose uptake. Animal Model: Obese hyperglycaemic mice [1] Dosage: 2-10 mpk Administration: Oral, twice daily, for a week Result: Decreased blood glucose, lowered blood glucose in a muscular AMPK-dependent manner reduced hepatic TAG, improved insulin sensitivity, increased glucose disposal rates, inhibited TAG synthesis in liver and primary hepatocytes, decreased fat mass. Animal Model: NASH mice [1] Dosage: 2 mpk Administration: Oral, twice-daily, for a month Result: Decreased histological scores used to describe the features of NASH, reduced apoptosis rate of hepatic cells, inhibited inflammatory responses in the liver of NASH mice and improved glucose tolerance of NASH mice. Animal Model: C. elegans [1] Dosage: 0-50 μM Administration: Oral, 0-50 days Result: Promoted oxidative stress resistance and mitochondrial functions in C. elegans. Animal Model: C57BL/6 mice [1] Dosage: 100 μg/mL Administration: Oral Result: Extended lifespan, elevated NAD ＋ levels and mitochondrial oxidative respiration, rejuvenated muscle function in aged mice. |
| 分子量 | 593.46 |
| 分子式 | C27H43Cl2IN2 |
| CAS No. | 2904601-67-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
DMSO: 60 mg/mL (101.1 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
参考文献
投与量変換You can also refer to dose conversion for different animals. 詳細
In vivo投与量計算 (透明溶液)計算器bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Aldometanib 2904601-67-6 Chromatin/Epigenetic Others PI3K/Akt/mTOR signaling AMPK CompoundIA47 Inhibitor inhibitor inhibit
